BRIEF-Puma Biotechnology Reports Q4 Loss Per Share $0.38
BRIEF-Puma Biotechnology Reports Q4 Loss Per Share $0.38
* PUMA BIOTECHNOLOGY REPORTS FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
* Q4 ADJUSTED NON-GAAP LOSS PER SHARE $0.14
* Q4 EARNINGS PER SHARE ESTIMATE $-0.29 -- REFINITIV IBES DATA
* Q4 LOSS PER SHARE $0.38
* Q4 REVENUE $52.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $52.8 MILLION
* NET NERLYNX REVENUE IN Q4 OF 2020 WAS $50.0 MILLION, VERSUS $58.7 MILLION IN Q4 OF 2019
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
Feb 25 (Reuters) - Puma Biotechnology Inc :
* PUMA BIOTECHNOLOGY REPORTS FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
* Q4 ADJUSTED NON-GAAP LOSS PER SHARE $0.14
* Q4 EARNINGS PER SHARE ESTIMATE $-0.29 -- REFINITIV IBES DATA
* Q4 LOSS PER SHARE $0.38
* Q4 REVENUE $52.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $52.8 MILLION
* NET NERLYNX REVENUE IN Q4 OF 2020 WAS $50.0 MILLION, VERSUS $58.7 MILLION IN Q4 OF 2019
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
路透2月25日电-彪马生物技术公司(Puma Biotechnology Inc)：*PUMA生物技术报告第四季度和全年财务业绩*第四季度调整后非GAAP每股亏损0.14美元*第四季度每股收益预估$-0.29-REFINITIV IBES数据*第四季度每股亏损0.38美元*第四季度收入为5260万美元，而REFINITIV IBES估计为5280万美元*2020年第四季度NERLYNX净收入为5000万美元，而2019年第四季度为5870万美元Eikon的源文本：进一步的公司报道：(Reurs.Briefs@thomsonreurs.com；)
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧